NFKB1 and breast carcinoma: However, the potential use of NFκB inhibitors in cases of breast cancer with bone metastases needs to be carefully explored so that any treatment regime would take into consideration and exploit both, their cell-autonomous effects in the bone microenvironment and their direct effects on tumour.